An empirical approach towards the efficient and optimal production of influenza-neutralizing ovine polyclonal antibodies demonstrates that the novel adjuvant CoVaccine HT™ is functionally superior to Freund's adjuvant.

However when ELISA data from all time points including twelve weeks post-immunisation were analysed, a significant trend for higher antibody titres was observed in the subcutaneously primed group ( Figure 1A ; P<0.05), which may indicate a slower decline in antibody titre for this group.

also in 9,775 other papers